Acute versus chronic phase mechanisms in a rat model of CRPS.
Palo Alto, United States. In J Neuroinflammation, Dec 2015
However, spinal levels of NK1 receptor, TNFα, IL-1β, and NGF were elevated at 4 and 16 weeks, and intrathecal injection of an NK1-receptor antagonist (LY303870), anakinra, or anti-NGF each reduced nociceptive behaviors at both 4 and 16 weeks.
Rolapitant: First Global Approval.
Auckland, New Zealand. In Drugs, Nov 2015
UNASSIGNED: Rolapitant (Varubi™) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.